Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.

PMID:
15502839
2.

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. Epub 2005 Jan 21. Review.

PMID:
15687027
3.

Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.

Singh S, Saraav I, Sharma S.

Vaccine. 2014 Feb 3;32(6):712-6. doi: 10.1016/j.vaccine.2013.11.065. Epub 2013 Dec 2. Review.

PMID:
24300592
4.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
5.

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.

Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, Hill AV, Adegbola RA, McShane H.

Lancet Infect Dis. 2006 Aug;6(8):522-8. Review.

PMID:
16870530
6.

MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults.

Nicol MP, Grobler LA.

Curr Opin Mol Ther. 2010 Feb;12(1):124-34. Review.

PMID:
20140824
7.

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV.

Vaccine. 2006 May 22;24(21):4554-61. Epub 2005 Aug 24. Review.

PMID:
16150517

Supplemental Content

Support Center